Will Orlady represents biopharmaceutical, medical device, and technology companies in high-stakes intellectual property litigation.

Will draws on experience at every stage of litigation to advance or defend his client’s intellectual property claims. His practice covers disputes involving patent infringement, trade secret misappropriation, and intellectual property licensing and ownership (including related arbitration). Will has successfully represented both plaintiffs and defendants in disputes involving:

  • Small molecule drugs
  • Antibodies
  • Vaccines
  • Antibody-drug conjugates (ADCs)
  • Medical devices and other technologies

He regularly leads teams in litigation matters in district courts nationwide, the International Trade Commission (ITC), and in arbitration. Having been a central team member at eight trials, Will’s practice routinely involves complex, multijurisdictional disputes with global implications for his clients.

Will’s dedicated and team-driven approach stems from his time as a Division I swimmer. Will has deep experience spanning all phases of litigation, including pre-suit diligence, fact and expert discovery, claim construction, dispositive motions, and post-trial briefing, as well as preparing for, defending, and taking important fact and expert depositions. 

In addition to his intellectual property practice, Will dedicates his time to pro bono matters and is a member of the PTAB Bar Association.

Will’s experience includes representing:

  • Sarepta in litigation involving novel treatments for Duchenne muscular dystrophy, resulting in a complete jury trial win
  • AbbVie in:
    • BPCIA litigation involving Humira®
    • District court litigation and in arbitration related to AbbVie innovative hepatitis C virus treatments Mavyret®, Viekira Pak®, and Technivie®
  • Intellia Therapeutics in litigation relating to CRISPR/Cas9 gene editing technology
  • Regeneron in patent litigation involving its groundbreaking antibody treatment for COVID-19 (REGENCOV®)
  • Merck Sharp & Dohme in a trade secret litigation relating to polysaccharide-protein conjugate vaccine formulations
  • A global pharmaceutical company in a competitor patent litigation involving multiple sclerosis drug products
  • A global pharmaceutical company in a confidential arbitration and license dispute relating to ADC technology
  • Philip Morris & Altria in a multi-jurisdictional dispute on innovative “heat-not-burn” and e-vapor technologies
  • Jaguar Land Rover in multi-forum patent litigation involving vehicle control technology
  • A multinational software company in a case that Latham took over following summary judgment and stipulation of direct infringement only four months before jury trial; obtained jury verdict of no induced infringement and judgment of zero damage

Bar Qualification

  • California
  • District of Columbia

Education

  • JD, University of Minnesota Law School, 2016
    magna cum laude
  • BA in Neuroscience, University of Southern California, 2012
  • BA in Psychology, University of Southern California, 2012